

Edgar Filing: GERON CORPORATION - Form 8-K

GERON CORPORATION  
Form 8-K  
April 07, 2003

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 7, 2003

GERON CORPORATION

(Exact name of registrant as specified in its charter)

|   |                                     |   |
|---|-------------------------------------|---|
| Delaware<br>(State or Other Jurisdiction<br>of Incorporation) | 0-20859<br>(Commission File Number) | 75-2287752<br>(IRS Employer<br>Identification Number) |
|---|-------------------------------------|---|

|  |                     |
|--|---------------------|
| 230 Constitution Drive<br>Menlo Park, California<br>(Address of principal executive offices) | 94025<br>(Zip Code) |
|--|---------------------|

(650) 473-7700  
(Registrant's telephone number, including area code)

N/A  
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On April 7, 2003, Geron Corporation, a Delaware corporation (the "Company"), announced that it will present the positive preliminary results from a Phase 1 clinical trial of telomerase immunotherapy for metastatic prostate cancer on a webcast conference call on, April 7, 2003 at 9:00 am Pacific Daylight Time. The data were originally to be presented at the American Association of Cancer Research (AACR) annual meeting in Toronto, which was cancelled last week due to the outbreak of SARS.

The Company's press release announcing the webcast conference call and the preliminary results is filed as an exhibit to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the document filed as an exhibit hereto.

Item 7. Exhibits.

Exhibits

-----

99.1 Press Release dated April 7, 2003.

Edgar Filing: GERON CORPORATION - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: April 7, 2003

By: /s/ William D. Stempel

-----  
Name: William D. Stempel

Title: Vice President and General Counsel

EXHIBIT INDEX

Exhibits

-----

99.1

Press Release dated January 21, 2003